Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500820 · ClinicalTrials.gov registry record · Phase 1
Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05500820 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 56 participants.
The verdict
NCT05500820, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.
Interventions
- DRUG Matching Placebo
- DRUG CIN-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05500820
The ClinicalTrials.gov registry entry for NCT05500820 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05500820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05500820 about?
NCT05500820 is a clinical study titled "Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy Subjects". This is a randomized, double-blind, study to assess the safety, tolerability, PK, and PD of multiple oral doses of CIN-107 when administered to healthy adult subjects.
What is the current status of trial NCT05500820?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-12-19. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT05500820?
The interventions under investigation include: Matching Placebo (DRUG), CIN-107 (DRUG).
Who is sponsoring clinical trial NCT05500820?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.